Navigation Links
Alzheimer’s Disease: Landmark Gene Discoveries Open Up New Therapeutic Opportunities
Date:9/23/2013

Boston, MA (PRWEB) September 23, 2013

In a paper recently published in the prestigious journal Neuron, Harvard Medical School/Mass General Hospital Geneticist Dr. Rudy Tanzi, together with lead author, Dr. Jaehong Suh and their team, identified two rare mutations in the human gene called "ADAM10" that lead to the most common, late-onset variant of Alzheimer's. Tanzi's research suggests that the ADAM10 gene makes an enzyme called alpha-secretase, which cleaves the Amyloid Precursor Protein (APP) to prevent the formation of beta-amyloid, the toxic protein that triggers brain pathology in Alzheimer's disease.

This landmark genetic discovery by Tanzi, who is also Research Consortium Chair at Cure Alzheimer' Fund, further supports the widely-held "Amyloid Hypothesis" and suggests specific new therapeutic approaches to stopping Alzheimer's disease.

In their study, Tanzi and Suh first identified two new human gene mutations in ADAM10 and then inserted them into Alzheimer's mouse models to track their effects in the brain. Subsequently, the team was able to demonstrate how the mutant genes diminish alpha-secretase activity leading to increased levels of beta-amyloid, the main component of senile plaques in Alzheimer’s disease.

These findings are the first to document novel Alzheimer's gene mutations in animal models since the mutations in the original four Alzheimer's genes -- APP, PSEN1, PSEN2, and APOE -- were discovered in the 1990’s.

Furthermore, the effects in mouse brains strongly suggest that diminished alpha-secretase activity owing to the ADAM10 gene mutations causes Alzheimer's and therefore supports ADAM10 as a promising therapeutic target for the treatment and prevention of the disease. "If we can find or develop a drug to safely increase alpha-secretase activity," said Tanzi, "that would decrease the accumulation of beta-amyloid plaques and slow down or even stop the onset of the disease."

Cure Alzheimer’s Fund President and CEO Tim Armour said, "These discoveries are validation of the aggressive gene-centric approach long supported by Cure Alzheimer's Fund. With this new data, we have two more important pieces filling out the large puzzle of how Alzheimer's disease develops in the human brain. It's that much closer to a complete picture, and brings us that much closer to a cure."

About Cure Alzheimer’s Fund

The Cure Alzheimer’s Fund is governed by a board of directors; administered by a small, full-time staff; and guided scientifically by a Research Consortium. Cure Alzheimer's Fund™ is a 501(c)(3) public charity. Cure Alzheimer’s Fund has supported 72 projects in 51 laboratories of leading Alzheimer’s researchers in the US and abroad.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11146480.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. NIH Grant to support Mount Sinai Research Program to Create Biological Network Model of Alzheimer’s Disease in partnership with New York Stem Cell Foundation
2. Fort Worth Senior Care Company Will Walk to Support the Alzheimer’s Association
3. Congratulations Congresswoman Maxine Waters for Being Named Co-chair of the Alzheimer’s Task Force;* Now it is Time to Broadly Implement the Treatment that Reverses and Stabilizes this Disease
4. North Seattle Retirees Raise ‘Fair’ Funds for Alzheimer’s Association
5. Heritage Woods of South Elgin Affordable Assisted Living to Host Alzheimer’s Walk
6. Jane Hill Gives Hope and Help to Alzheimer’s Sufferers and Caregivers
7. Senior Moments a Prelude to Alzheimer’s: Not Necessarily - Your Physician Can Enable Evidenced Based Preventive Steps With OTC Supplements
8. Researchers Identify New Genes Linked to the Origins of Alzheimer’s, Says Cure Alzheimers Fund
9. RSNA: Concussion Patients Show Alzheimer’s-like Brain Abnormalities
10. World Leaders in Alzheimer’s Innovation to Discuss Progress, Collaboration at DIA Annual Meeting
11. Mediaplanet Releases a Campaign to Reflect on 100 Years of Alzheimer’s Research and the Quest for a Cure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... Today, MTI-GlobalStem, a provider of optimized transfection ... to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing System ... is a complete system for culturing and transfecting human pluripotent stem cells for ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... and infrastructure. Most providers, however, are unsure how to move forward, given the ... to define a path forward tailored to an organization’s specific needs. , PYA ...
(Date:6/24/2016)... ... ... SpiritQuest Sedona Retreats, located in Arizona has re-located to 75 Kallof Place, ... Rock, Airport Mesa, and Boynton Canyon. The new retreat center is ideally-situated ... the Sedona Rouge, both popular accommodations for SpiritQuest clients. The Medicine Wheel, Labyrinth ...
(Date:6/23/2016)... ... 2016 , ... An article published June 8 on AOL News ... neck cancer in individuals with unhealthy oral hygiene habits. The article goes on to ... had gum disease, brushed their teeth on a daily basis, wore dentures and if ...
(Date:6/23/2016)... ... June 23, 2016 , ... SyncDog, Inc. ... mobile security software, is featured in the current issue of Silicon Review ... companies with innovative technology solutions and features them in their magazine. The magazine ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology: